The company remains entirely pre-revenue, with consistent quarterly operating losses ranging between $1.4 million and $2.4 million over the last ten quarters.
| Sales/Revenue | 0 | 0 | 0 | 0 | 249.04K | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | -100% | - | - | - | - |
| Cost of Goods Sold | 98.37K | 0 | 0 | 0 | 200.13K | 0 | 157.04K | 142.97K |
| COGS % of Revenue | - | - | - | - | 80.36% | - | - | - |
| Gross Profit | -98.37K | 0 | 0 | 0 | 48.91K | 0 | -157.04K | -142.97K |
| Gross Margin % | - | - | - | - | 19.64% | - | - | - |
| Gross Profit Growth % | - | - | - | -100% | - | 100% | -9.84% | - |
| Operating Expenses | 6.9M | 6.95M | 7.17M | 10.31M | 9.37M | 3.23M | 1.04M | 1.49M |
| OpEx % of Revenue | - | - | - | - | 3761.12% | - | - | - |
| Selling, General & Admin | 3.93M | 3.91M | 3.7M | 4.6M | 5.21M | 2.08M | 669.14K | 1.18M |
| SG&A % of Revenue | - | - | - | - | 2093.85% | - | - | - |
| Research & Development | 3.07M | 3.05M | 3.47M | 5.71M | 4.15M | 1.15M | 527.25K | 454.61K |
| R&D % of Revenue | - | - | - | - | 1667.26% | - | - | - |
| Other Operating Expenses | -98.37K | 0 | 0 | 0 | 0 | 0 | -157.04K | -142.97K |
| Operating Income | -7M | -6.95M | -7.17M | -10.31M | -9.32M | -3.23M | -1.2M | -1.63M |
| Operating Margin % | - | - | - | - | -3741.48% | - | - | - |
| Operating Income Growth % | - | 3.02% | 30.47% | -10.66% | -188.46% | -169.99% | 26.67% | - |
| EBITDA | -6.83M | -6.78M | -6.97M | -9.53M | -9.01M | -3.08M | -1.04M | -1.49M |
| EBITDA Margin % | - | - | - | - | -3618.46% | - | - | - |
| EBITDA Growth % | -6.18% | 2.7% | 26.86% | -5.76% | -192.16% | -196.77% | 30.17% | - |
| D&A (Non-Cash Add-back) | 168.35K | 170.68K | 199.1K | 780.96K | 306.37K | 145.72K | 157.04K | 142.97K |
| EBIT | -6.92M | -6.85M | -6.89M | -9.95M | -9.32M | -3.12M | -1.2M | -1.63M |
| Net Interest Income | 98.01K | 96.72K | -677.21K | 164.9K | 89.67K | 145.84K | 116.67K | 52.28K |
| Interest Income | 98.62K | 97.56K | 145.82K | 164.9K | 89.67K | 513.3K | 143.67K | 52.28K |
| Interest Expense | 609 | 839 | 823.03K | 0 | 0 | 367.46K | 27K | 0 |
| Other Income/Expense | 96.72K | 104.49K | -548.18K | 357.33K | 20.83K | -258.13K | 38.11K | 811.57K |
| Pretax Income | -6.9M | -6.85M | -7.72M | -9.95M | -9.3M | -3.49M | -1.16M | -819.84K |
| Pretax Margin % | - | - | - | - | -3733.11% | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -6.9M | -6.85M | -7.72M | -9.95M | -9.3M | -3.73M | -1.13M | -757.72K |
| Net Margin % | - | - | - | - | -3733.11% | - | - | - |
| Net Income Growth % | 4.83% | 11.26% | 22.46% | -7.07% | -149.27% | -231.32% | -48.57% | - |
| Net Income (Continuing) | -6.9M | -6.85M | -7.72M | -9.95M | -9.3M | -3.49M | -1.16M | -819.84K |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -15.37 | -15.25 | -456.76 | -290.48 | -292.88 | -118.68 | -56.76 | -38.20 |
| EPS Growth % | 97.06% | 96.66% | -57.24% | 0.82% | -146.78% | -109.09% | -48.59% | - |
| EPS (Basic) | - | -15.25 | -456.76 | -290.48 | -292.88 | -118.68 | -56.76 | -38.20 |
| Diluted Shares Outstanding | 449.04K | 449.04K | 45.85K | 34.27K | 31.51K | 31.43K | 19.84K | 19.84K |
| Basic Shares Outstanding | 449.04K | 449.04K | 45.85K | 34.27K | 31.51K | 31.43K | 19.84K | 19.84K |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Imminent liquidity and regulatory risk
As indicated by the company's financial statements over the last ten quarters, Bluejay Diagnostics remains entirely pre-revenue, with zero top-line generation reported. This lack of commercial activity underscores the developmental nature of the firm, as it continues to focus exclusively on clinical validation and regulatory milestones.
The absence of revenue suggests that the company has yet to transition from a research-oriented entity to a commercial enterprise. Investors should monitor the timeline for FDA 510(k) clearance, as this remains the primary catalyst required to initiate the transition toward a recurring revenue model.
Based on reported quarterly figures, the company consistently incurs significant operating expenses, with R&D and SG&A spending frequently exceeding $1.5 million per quarter. This persistent cost structure reflects the heavy investment required for clinical trials and the maintenance of essential licensing agreements with third-party technology providers.
The high level of fixed operating costs relative to the lack of revenue indicates a high burn rate that necessitates frequent capital market access. Management's expense discipline appears focused on sustaining core development, yet the lack of operational scale suggests that these costs will remain a significant drag on future earnings.
According to the income statement data, the company reports negative operating income in every period, with losses ranging from $1.4 million to $2.4 million per quarter. This consistent operating deficit highlights the absence of any meaningful operating leverage as the firm continues to fund its pre-commercial activities.
The inability to scale operating income is a direct consequence of the pre-revenue status, where every dollar spent on R&D and SG&A flows directly to the bottom line as a loss. Until the Symphony platform achieves market entry, the company will likely remain unable to demonstrate any positive operating leverage.
As evidenced by the historical EPS figures, which show extreme volatility and significant negative values, the quality of earnings is currently obscured by the company's reliance on equity financing. The frequent need for capital raises suggests that shareholders face ongoing dilution risks that complicate traditional earnings analysis.
The reported net losses are a reflection of the company's developmental stage rather than operational inefficiency alone. Analysts should focus on the cash burn rate and the potential for further dilutive financing, as these factors are more indicative of the company's current financial health than the reported EPS.
Based on the reported cash position of approximately $5.16 million, the company's current financial trajectory appears unsustainable without near-term capital infusion. This limited runway poses a significant risk to the company's ability to complete its clinical trials and achieve the necessary regulatory milestones for commercialization.
Short-sellers would likely focus on the high probability of dilutive equity offerings required to sustain operations. The reliance on external technology partners for core components further complicates the risk profile, as any disruption in supply could exacerbate the existing financial pressure.
Quick answers to the most common questions about buying BJDX stock.
For fiscal year 2025, Bluejay Diagnostics, Inc. (BJDX) reported total revenue of $0.0M.
Bluejay Diagnostics, Inc. (BJDX) reported a net loss of $6.8M for the fiscal year ending 2025.